Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

By The Northwire Desk — AI Analysis Mar 23, 2026 · 07:30 APS · 2.23 APTOSE BIOSCIENCES INC.
APS · Price

Executive Summary

  • Glass Lewis recommends Aptose shareholders vote “FOR” the proposed acquisition of all outstanding Aptose common shares by Hanmi Pharmaceutical and its subsidiary.
  • The special shareholder meeting has been reconvened to March 31, 2026 (virtual) with a voting deadline of 11:00 a.m. EST on March 27, 2026.
  • Completion of the transaction remains subject to customary closing conditions, including court approval and TSX clearance.

Key Details

  • Transaction: Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd. (collectively “Hanmi Purchasers”) will acquire 100% of Aptose’s outstanding common shares not already owned by them.
  • Proxy Recommendation: Glass Lewis, an independent proxy advisory firm, advises shareholders to vote “FOR” the Arrangement Resolution and the Continuance Resolution (conversion from CBCA to ABCA corporation).
  • Board Position: Aptose’s Special Transaction Committee and Board of Directors unanimously recommend voting “FOR” both resolutions.
  • Meeting Information:
  • Reconvened special meeting date: March 31, 2026 at 11:00 a.m. EST (virtual audio webcast).
  • Record date for voting eligibility: close of business on February 24, 2026.
  • Proxy deadline: 11:00 a.m. EST on March 27, 2026.
  • Regulatory Context: Meeting reconvened after SEC comments on the Schedule 13E‑3 filing; an interim court order (Dec 12, 2025) authorizes the meeting.
  • Closing Conditions: Transaction subject to customary conditions, including:
  • Final court approval.
  • TSX (Toronto Stock Exchange) approval.
  • Satisfaction of any other regulatory or shareholder approvals.
  • Shareholder Assistance: Morrow Sodali (Canada) Ltd. retained to assist with proxy solicitation; contact details provided for voting assistance.

Notable Quotes

(No direct CEO/President quotes included in the release.)

Read the original news release →

More from APTOSE BIOSCIENCES INC.

Jun 30, 2026 · 19:32

Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

M&A / Property Jun 15, 2026 · 07:30

Clinical data validates tuspetinib's AML potential, but acquisition hinges on delayed Korean regulatory approval.

Other May 29, 2026 · 07:30

Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles

Financings May 13, 2026 · 17:00

Hanmi Acquisition Delayed to May 2026 as Aptose Burns Cash Faster Than Expected

Earnings Apr 30, 2026 · 07:30

Hanmi Acquisition Closing Delayed to May as Korean Regulatory Review Continues

M&A / Property Mar 31, 2026 · 17:22

Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy

Earnings